Blood filter trial offers new hope for chronic fatigue sufferers
NCT ID NCT05710770
First seen Jan 20, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study tested whether a procedure called immunoadsorption, which filters certain antibodies from the blood, can reduce fatigue in people with chronic fatigue syndrome (ME/CFS), including those with post-COVID CFS. 66 adults with confirmed autoantibodies received either five real treatments or sham treatments over 10 days, then were followed for 6 months. The main goal was to see if fatigue scores improved at 3 months, and to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ME/CFS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.